## MRTX-EX185 formic

Cat. No.:	HY-145962/	4	
		•	
Molecular Formula:	C <sub>34</sub> H <sub>35</sub> FN <sub>6</sub> O	4	
Molecular Weight:	610.68		
Target:	Ras		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month

### SOLVENT & SOLUBILITY

In Vitro DMSO: 125 mg/mL (2) Preparing Stock Solutions Please refer to the so	DMSO : 125 mg/mL (204.69 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.6375 mL	8.1876 mL	16.3752 mL	
		5 mM	0.3275 mL	1.6375 mL	3.2750 mL	
	10 mM	0.1638 mL	0.8188 mL	1.6375 mL		
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent Solubility: 2.08 mg	one by one: 10% DMSO >> 90% (20 g/mL (3.41 mM); Suspended solution	% SBE-β-CD in saline) ; Need ultrasonic			

DIOLOGICALACTIV	
Description	MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC <sub>50</sub> of 90 nM for KRAS(G12D). MRTX- EX185 formic also binds GDP-loaded HRAS <sup>[1]</sup> . MRTX-EX185 (formic) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
IC <sub>50</sub> & Target	KRas G12D 90 nM (IC <sub>50</sub> )

#### REFERENCES

[1]. Vasta JD, et, al. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Nat Chem Biol. 2022 Mar 21.

# Product Data Sheet

ОН

О<sub>≫</sub>ОН



#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA